Stockreport

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF - Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stab [Read more]